Valuation: TegoScience Inc.

Market Cap 53.24B 37.78M 32.68M 30.51M 27.99M 52.65M 3.6B 53.49M 358M 141M 1.8B 142M 139M 5.96B P/E 2024
29.9x
P/E 2025 -18.6x
Enterprise Value 17.96B 12.74M 11.02M 10.29M 9.44M 17.76M 1.21B 18.04M 121M 47.4M 608M 47.85M 46.8M 2.01B EV / Sales 2024
11x
EV / Sales 2025 16x
Free-Float
56.89%
Yield 2024 *
-
Yield 2025 -
05-18 TegoScience Inc. agreed to acquire 95.77% stake in PNP Pharm Co., Ltd. for KRW 3.7 billion. CI
26/05/25 TegoScience Inc. announced that it has received KRW 27 billion in funding CI
22/05/25 TegoScience Inc. announced that it expects to receive KRW 27 billion in funding CI
18/09/23 TegoScience Inc.(KOSDAQ:A191420) dropped from S&P Global BMI Index CI
21/03/23 TegoScience Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
14/03/22 TegoScience Inc.'s Equity Buyback announced on March 16, 2020, has expired. CI
14/03/21 TegoScience Inc.'s Equity Buyback Plan Extended till September 15, 2021. CI
14/09/20 TegoScience Inc.'s Equity Buyback Plan Extended till March 15, 2021. CI
19/06/20 Tranche Update on TegoScience Inc.'s Equity Buyback Plan announced on March 16, 2020. CI
16/03/20 TegoScience Inc. announces an Equity Buyback for KRW 2,000 million worth of its shares. CI
15/03/20 Tego Science, Inc. authorizes a Buyback Plan. CI
20/10/16 TegoScience Inc. announced that it has received KRW 15 billion in funding from Korea Investment Capital Co., Ltd, LIG Investment & Securities Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm CI
18/10/16 TegoScience Inc. announced that it expects to receive KRW 15 billion in funding from Korea Investment Capital Co., Ltd, LIG Investment & Securities Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm CI
1 day+2.47%
1 week+5.89%
Current month+5.89%
1 month-0.45%
3 months-49.47%
6 months-53.20%
Current year-59.20%
1 week 6,090
Extreme 6090
6,750
1 month 5,230
Extreme 5230
6,960
Current year 5,230
Extreme 5230
16,500
1 year 5,230
Extreme 5230
19,370
3 years 5,230
Extreme 5230
26,100
5 years 5,230
Extreme 5230
30,300
10 years 5,230
Extreme 5230
73,500
Manager TitleAgeSince
Chief Executive Officer 60 19/03/2001
Corporate Officer/Principal 53 -
Comptroller/Controller/Auditor 65 -
Director TitleAgeSince
Director/Board Member 60 19/03/2001
Director/Board Member 63 19/03/2001
Director/Board Member 53 30/04/2001
Change 5-day change 1-year change 3-year change Capi.($)
+2.47%+5.89%-60.77%-29.03% 37.78M
+1.59%+2.85%+39.32%+0.52% 78.32B
+2.77%+4.78%-0.98%+28.10% 51.1B
-0.84%+0.09%+20.92%+175.02% 49.18B
-0.13%+7.42%-49.33%-50.09% 44.71B
+0.80%+2.46%+59.13%-24.15% 30.72B
+1.84%+0.87%+53.80%+86.83% 24.44B
+9.86%+7.94%+126.53%-40.68% 23.62B
+4.29%+9.40%+3.95%+230.49% 21.05B
+1.66%-3.70%+66.13%+121.72% 16.61B
Average +2.43%+4.57%+25.87%+49.87% 33.98B
Weighted average by Cap. +1.88%+4.29%+26.93%+44.54%

Financials

2024 2025
Net sales 6.76B 4.8M 4.15M 3.87M 3.55M 6.68M 456M 6.79M 45.45M 17.84M 229M 18.01M 17.61M 756M 5.94B 4.21M 3.65M 3.4M 3.12M 5.87M 401M 5.97M 39.95M 15.68M 201M 15.83M 15.48M 665M
Net income 3.35B 2.38M 2.06M 1.92M 1.76M 3.31M 226M 3.36M 22.52M 8.84M 113M 8.92M 8.73M 375M -7.01B -4.98M -4.3M -4.02M -3.69M -6.93M -474M -7.04M -47.15M -18.51M -237M -18.68M -18.27M -785M
Net Debt -25.58B -18.15M -15.7M -14.66M -13.45M -25.3M -1.73B -25.7M -172M -67.52M -866M -68.16M -66.67M -2.86B -35.28B -25.03M -21.65M -20.22M -18.55M -34.89M -2.38B -35.45M -237M -93.12M -1.19B -94.01M -91.95M -3.95B
Logo TegoScience Inc.
Tego Science Inc is a Korea-based company principally engaged in the manufacture and distribution of biopharmaceuticals. The Company is principally engaged in the research, development, manufacture and distribution of cell therapy products used for the treatment of third-degree and severe burns, deep second-degree burns, diabetic foot ulcers and under-eye wrinkles. The Company is engaged in the manufacture and sale of artificial skins used for testing the efficacy and safety of pharmaceuticals and cosmetics as well as for screening new drugs. In addition, the Company is engaged in the provision of biopharmaceutical contract manufacturing and development organization (CDMO) services and experimental services. The Company is also engaged in the property rental.
Employees
-
Date Price Change Volume
07/08/26 ₩6,650.00 +2.47% 3,156
06/08/26 ₩6,490.00 +1.25% 1,858
05/08/26 ₩6,410.00 -1.84% 1,839
04/08/26 ₩6,530.00 +7.05% 2,819
03/08/26 ₩6,100.00 -2.87% 1,996
  1. Stock Market
  2. Stocks
  3. A191420 Stock